Oral Genome, a biotechnology company, announced a partnership with Henry Schein, a leading global provider of office-based dental and healthcare services.
Through this partnership, Oral Genome’s mobile-compatible saliva testing kit will be available through Henry Schein’s distribution network in dental offices, community health centers, and healthcare facilities.
The test provides clinical-grade results in less than 15 minutes, requiring no laboratory processing, and covers key salivary biomarkers associated with conditions such as cavities, periodontal disease, and diabetes.
Dirk Benson, President of Henry Schein’s U.S. Distribution Group, said, “Expanding our point-of-care diagnostic services aligns with our mission to advance prevention and wellness through a systems health model. Oral genomics provides dentists and physicians with a powerful tool to enhance patient care.”
Dr. Tina Saw, CEO of Oral Genome, added, “Our point-of-care tests provide healthcare practitioners with actionable insights, transforming everyday office visits into opportunities to improve overall health.”
Notably, this is not Henry Schein’s first foray into saliva testing. In 2024, the company announced that it would distribute Viome’s Oral Health Pro with CancerDetect test for screening for oral and throat cancer.